A recent in vivo study demonstrated that CAR-T therapy modified to possess a receptor tyrosine kinase-like orphan 1 (ROR1) receptor induced a significant decrease in tumor volume and weight in a subcutaneous mouse model of pancreatic cancer featuring ROR-1-expressing Panc02 cells. The gene discussed is ROR1; the disease is pancreatic neoplasm.